eMedAlcohol: Alcohol Addiction: A Systems-oriented Approach

Sponsor
Charite University, Berlin, Germany (Other)
Overall Status
Completed
CT.gov ID
NCT02910193
Collaborator
Central Institute of Mental Health, Mannheim (Other)
159
1
36.3
4.4

Study Details

Study Description

Brief Summary

The goal of the multicenter subproject (SP) 10 of the eMED Alcohol Addiction Consortium - A Systems-Oriented Approach is to study neuroimaging x genetics predictions in an existing sample (NGFNplus) of tightly endophenotyped and genome-wide genotyped alcohol dependent subjects (N=240) and controls (N=240); (ii) to translate the results of neuroimaging and genetic analyses from an adolescent risk sample (IMAGEN) to adult disease (NGFNplus sample) by examining related MRI-paradigms tagging the same functional brain systems in both samples (e.g. reward system, inhibitory control system, emotion processing, working memory); (iii) to conduct a follow-up neuroimaging study on the NGFNplus sample validating the neurobehavioral risk profiles predictive for juvenile harmful alcohol use in adult patients with alcohol addiction, (iv) to expand the NGFNplus sample by including a new set of healthy subjects with high genetic risk (1st degree relatives of patients with alcohol addiction). The investigators will do so by using elaborate imaging genetic methods that are already available and successfully used in other multicenter studies by the investigator's research group (e.g. univariate analyses, functional and effective connectivity analyses, polygenetic scores, network topology) as well as by using complex computational algorithms and mathematical models, in particular advanced machine learning methods, developed in SP 6. The investigator's approach aims in the long to predict and characterize longitudinal outcomes in patients with alcohol addiction (5 years following our index session) and to complement the NGFN-sample with an add-on study with 1st degree relatives that will allow the investigators to test the generalizability of the identified predictive risk profiles for early risk identification.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    The overall research goal of this project is (i) to study neuroimaging x genetics predictions in an existing sample (NGFNplus) of tightly endophenotyped and genome-wide genotyped alcohol dependent subjects (N=240) and controls (N=240); (ii) to translate the results of neuroimaging x genetic analyses from an adolescent risk sample (IMAGEN) to adult disease (NGFNplus sample) by examining related paradigms tagging the same functional systems in both samples; (iii) to conduct a follow-up neuroimaging study on the NGFNplus sample validating the neurobehavioral risk profiles predictive for harmful alcohol use in adolescents in adult patients with alcohol addiction (iv) to expand the NGFNplus sample by including a new set of healthy subjects with high genetic risk (1st degree relatives of patients with alcohol addiction). The investigators will do so by using imaging genetic methods that are already available and used in other multicenter studies by the investigator's research group (e.g. univariate analyses, functional and effective connectivity analyses, polygenetic scores, network topology) as well as by using computational algorithms and mathematical models, in particular advanced machine learning methods, developed in other sub projects (SPs) of the consortium in particular of SP4 and SP6. The investigator's approach will enable the researchers to characterize outcome longitudinal in patients with alcohol addiction (5 years following our index session) and to complement the NGFN-sample with an add-on study with 1st degree relatives that will allow the investigators to test the generalizability of the identified predictive risk profiles for early risk identification.

    Study Design

    Study Type:
    Observational [Patient Registry]
    Actual Enrollment :
    159 participants
    Observational Model:
    Cohort
    Time Perspective:
    Cross-Sectional
    Official Title:
    Alcohol Addiction: A Systems-oriented Approach; Functional Validation II: Neuroimaging x Genetics
    Actual Study Start Date :
    May 17, 2016
    Actual Primary Completion Date :
    May 27, 2019
    Actual Study Completion Date :
    May 27, 2019

    Arms and Interventions

    Arm Intervention/Treatment
    alcohol-dependent patients

    first-degree relatives

    Parents, children, siblings of alcohol-dependent patients

    healthy control subjects

    Outcome Measures

    Primary Outcome Measures

    1. Functional brain imaging assessed using a Siemens Magnetom TimTrio, 3 Tesla [3 year]

      The primary outcome measure "Blood Oxygenation Level-Dependent (BOLD) response" will be assessed as a marker of neural activation via functional brain imaging (fMRI) during the processing of emotional, monetary and alcohol-associated cues as well as cognitive demand and at rest. A Siemens Magnetom TimTrio, 3 Tesla will be used.

    2. Structural brain imaging assessed using a Siemens Magnetom TimTrio, 3 Tesla [3 year]

      The second primary outcome measure "brain tissue (Grey Matter, White Matter, Cerebrospinal fluid)" will be assessed and quantified via structural brain imaging using magnet resonance tomography as well as defusion-tensor imaging (MRI, DTI). A Siemens Magnetom TimTrio, 3 Tesla will be used.

    Secondary Outcome Measures

    1. Assessment of genetic candidate markers and epigenetic markers of alcohol use disorders [3 years]

      Secondary outcome measures will be genotype specification of candidate SNPs (e.g. BDNF, GATA4, OPRM1, D2/D1) derived from blood samples and according DNA/RNA array genotyping. Project aim is to conduct Genom-Wide Association Studies (GWAS) to investigate genetic factors that may predispose to or protect against alcohol use disorder. Further epigenetic methylation factors (i.e. homocysteine serum level) will be investigated to differentiate between healthy controls, alcohol-dependent patients and individuals at risk (first grade relatives).

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 75 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • written informed consent

    • right handedness

    • no psychiatric disorders according to the International Classification of Diseases, Version 10 (ICD-10) (in patients: other than nicotine and alcohol dependence)

    • no use of psychotropic substances during previous 3 months

    Exclusion Criteria:
    • severe illnesses (e.g. neurological diseases)

    • MR-contraindications (e.g. pacemaker, metal or electronic implants, metal splinters)

    • no psychiatric axis I-disorders according to the International Classification of Diseases, Version 10 (ICD-10) (in patients: other than nicotine and alcohol dependence)

    • no use of psychotropic substances during previous 3 months

    • insufficient language knowledge

    • claustrophobia

    • pregnancy in women

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Charite - Universitätsmedizin Berlin Berlin Germany 10117

    Sponsors and Collaborators

    • Charite University, Berlin, Germany
    • Central Institute of Mental Health, Mannheim

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    Responsible Party:
    Andreas Heinz, Prof., MD, PhD, Charite University, Berlin, Germany
    ClinicalTrials.gov Identifier:
    NCT02910193
    Other Study ID Numbers:
    • 01ZX1311E
    First Posted:
    Sep 21, 2016
    Last Update Posted:
    Jul 31, 2019
    Last Verified:
    Jul 1, 2019
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Keywords provided by Andreas Heinz, Prof., MD, PhD, Charite University, Berlin, Germany
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jul 31, 2019